Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health

被引：474
作者：
Chambers E.S. [1 ]
Preston T. [2 ]
Frost G. [1 ]
Morrison D.J. [2 ]
机构：
[1] Section for Nutrition Research, Faculty of Medicine, Imperial College London, 6th Floor, Commonwealth Building, Hammersmith Hospital, London
[2] Stable Isotope Biochemistry Laboratory, Scottish Universities Environmental Research Centre, University of Glasgow, East Kilbride, Glasgow
来源：
Current Nutrition Reports | 2018年 / 7卷 / 4期
基金：
英国生物技术与生命科学研究理事会; 英国科研创新办公室; 英国医学研究理事会;
关键词：
Appetite regulation; Blood pressure; Cardiovascular disease; Fermentation; Glucose homeostasis; Gut microbiome; Inflammation; Metabolic health; Obesity; Short-chain fatty acids;
D O I：
10.1007/s13668-018-0248-8
中图分类号：
学科分类号：
摘要：
Purpose of this Review: This review assesses the latest evidence linking short-chain fatty acids (SCFA) with host metabolic health and cardiovascular disease (CVD) risk and presents the latest evidence on possible biological mechanisms. Recent Findings: SCFA have a range of effects locally in the gut and at both splanchnic and peripheral tissues which together appear to induce improved metabolic regulation and have direct and indirect effects on markers of CVD risk. Summary: SCFA produced primarily from the microbial fermentation of dietary fibre appear to be key mediators of the beneficial effects elicited by the gut microbiome. Not only does dietary fibre fermentation regulate microbial activity in the gut, SCFA also directly modulate host health through a range of tissue-specific mechanisms related to gut barrier function, glucose homeostasis, immunomodulation, appetite regulation and obesity. With the increasing burden of obesity worldwide, the role for gut microbiota-generated SCFA in protecting against the effects of energy dense diets offers an intriguing new avenue for regulating metabolic health and CVD risk. © 2018, The Author(s).
引用
收藏
页码：198 / 206
页数：8
相关论文
共 94 条
[1]  
Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., Et al., Heart Disease and Stroke Statistics-2016 update: a report from the American Heart Association, Circulation, 133, 4, pp. e38-e360, (2016)
[2]  
Roth G.A., Johnson C.O., Abate K.H., Abd-Allah F., Ahmed M., Alam K., Et al., The burden of cardiovascular diseases among US states, 1990-2016, JAMA Cardiol, 3, 5, pp. 375-389, (2018)
[3]  
Bhatnagar P., Wickramasinghe K., Wilkins E., Townsend N., Trends in the epidemiology of cardiovascular disease in the UK, Heart, 102, 24, pp. 1945-1952, (2016)
[4]  
Global Atlas on Cardiovascular Disease Prevention and Control, (2015)
[5]  
Lancet, 387, 10026, pp. 1377-1396, (2016)
[6]  
Butland B., Jebb S., Kopelman P., McPherson K., Thomasforesight S.M.J., Tackling Obesities: Future Choices, (2009)
[7]  
Kelly T.N., Bazzano L.A., Ajami N.J., He H., Zhao J., Petrosino J.F., Correa A., He J., Gut microbiome associates with lifetime cardiovascular disease risk profile among Bogalusa Heart Study participants, Circ Res, 119, 8, pp. 956-964, (2016)
[8]  
Wang Z., Zhao Y., Gut microbiota derived metabolites in cardiovascular health and disease, Protein Cell, 9, pp. 416-431, (2018)
[9]  
Heianza Y., Ma W., Manson J.E., Rexrode K.M., Qi L., Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies, J Am Heart Assoc, 6, 7, (2017)
[10]  
Senthong V., Wang Z., Li X.S., Fan Y., Wu Y., Tang W.H., Et al., Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: The contributory role of intestinal microbiota in a COURAGE-like patient cohort, J am Heart Assoc, 5, 6, (2016)
12345678910